Home / Resources / Videos / ADA 2017 / Thomas Seck Part 9, Final Thoughts

Thomas Seck Part 9, Final Thoughts




In part 9, the conclusion of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the importance of adding diet and exercise to a treatment regimen.

Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.

Transcript of this video segment:

Steve: I want to thank you for your time. All this is very interesting.

Dr. Seck: You are welcome

Steve: if we go back 50 years, we only had one drug. And then it exploded: 1995 until today.

Dr. Seck: I fully agree with you. We have made tremendous progress in this space to provide more appropriate treatment options for patients.

Steve: One last thing I would like to say is that, every diabetes drug in the instructions it says along with physical activity and nutrition, this drug can be very effective. Have they done any studies showing where people actually were educated intensely and they had better nutrition and had physical activity and took Empagliflozin, compared to people that were not.

Dr. Seck: You know you raise a very important point. I am an endocrinologist and took care of lot of patients with type 2 diabetes and clearly the first step after diagnosis is to really advocate lifestyle changes with exercise and also diet changes. And that is standard of care. It is recommended by the ADA as well. So all the studies we are doing, there is a study related to glucose lowering that our initial phase 3 program were done in the context of patient education. So patients were first educated to really adhere to an approved diet and exercise regimen and then the randomization to the drug occurred.

Return to the main page.